Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system?

MELEK H., Cetinkaya G., ÖZER E., YENTÜRK E., SEVİNÇ T. E., BAYRAM A. S., ...Daha Fazla

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, cilt.56, sa.3, ss.604-611, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1093/ejcts/ezz044
  • Dergi Adı: EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.604-611
  • Anahtar Kelimeler: Pathological complete response, Induction treatment, Neoadjuvant treatment, CHEMOTHERAPY, MANAGEMENT, SURVIVAL, OUTCOMES, SURGERY, THERAPY
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

OBJECTIVES: Prognosis for patients with non-small-cell lung cancer (NSCLC) who, after neoadjuvant/induction and surgery, have a pathological complete response (pCR) is expected to be improved. However, the place of the pCR patients in the context of the tumour, lymph node and metastasis (TNM) staging system is still not defined. The aim of this study is to investigate the long-term survival of NSCLC patients with pCR and to find their appropriate staging category within the TNM staging system.